中国同辐(01763.HK):原子高科获中国证监会核准定向发行不超3210万股新股
格隆汇2月5日丨中国同辐(01763.HK)发布公告,公司旗下原子高科(430005)于2019年9月30日召开2019年第三次临时股东大会,会议审议通过了《关于审议股票发行方案的议案》及其相关议案。根据有关规定,此次股票定向发行需中国证监会的核准。
2019年11月20日,原子高科收到《中国证监会行政许可申请接收凭证》(192850号),证监会对原子高科本次定向发行股票的申请予以受理。
2020年2月5日,原子高科收到中国证监会核发的《关于核准原子高科股份有限公司定向发行股票的批复》(证监许可[2020]137号),核准原子高科定向发行不超过3,210万股新股,该批复自核准发行之日(2020年1月17日)起12个月内有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.